European Antibiotic Awareness Day 2017
Today we mark the 10th anniversary of the European Antibiotic Awareness Day, by raising awareness once more about the antimicrobial resistance (AMR) – one of the biggest threats to global health. Launched in June, the goal of the new One Health action plan is to preserve our ability to effectively treat infections in humans and animals. The key objectives are: 'Making the EU a best practice region'; 'Boosting research and innovation'; and 'Shaping the global agenda'. In addition, the Innovative Medicines Initiative is expected to call for research to understand the value of diagnostics and the obstacles to their uptake.
- Joint statement – Health Commissioner and Research Commissioner
- Health Research activities on antimicrobial resistance
- European Centre for Disease Prevention and Control – AMR portfolio
- EU action against antimicrobial resistance: EDCTP’s contribution
Directorate-General Research & Innovation and IMI at BIO-Europe 2017
DG Research & Innovation and the Innovative Medicines Initiative participated at the largest biotech event in Europe with a booth and a session. During this 3–day event, the booth attracted many visitors interested in the EU funding opportunities. Our session (EU funding for health research SMEs: the European Innovation Council and beyond) provided concrete examples of successful SME participation in EU–funded projects and informative insights and advice for applicants from EU policymakers.
- European Commission EU funding for health research SMEs
- Innovative Medicines Initiative
- European Innovation Council
- EIB Support in Life Sciences
- IMI beneficiary EBOMAN
Research & Innovation Projects for Policy (P4P) report on rare diseases online now
EU Framework Programmes have funded research on rare diseases for more than two decades. In FP7 and Horizon 2020, 164 projects have produced results and a selection of these were analysed in the context of the five policy challenges to develop five key policy recommendations.
The European and Developing Countries Clinical Trials Partnership – new calls open today
The latest quarterly EDCTP newsletter is out with information about the new calls and much more on past and future initiatives.
EU-funded project organises workshop on cancer diagnostics
The EUR 4.8 million EU-funded project Glass-Laser Multiplexed Biosensor (GLAM) organises the workshop ‘Key Enabling Technologies for Better Cancer Diagnosis’ on 7 November 2017 in Tel Aviv.
The project uses groundbreaking technology to develop a device that is a step towards truly personalised medicine. The photonic-based point-of-care device will help oncologists make better treatment decisions according to the patient’s needs in a non-invasive manner for cancer diagnosis. More on this and other interesting topics will be discussed during this workshop.
EUR 20 million EU funding to combat multi-drug resistant bacteria
The European Investment Bank and AntibioTx, a Danish biotech SME, signed a EUR 20m loan agreement to develop new antibiotic treatments for skin infections. The loan will co-finance clinical trials based on AntibioTX’ patent, the aim being to bring the product to the market in 2020-2021.
New action plan to foster development of advanced therapies
The European Commission and the European Medicines Agency (EMA) have published today a joint action plan to foster the development of advanced therapy medicinal products (ATMPs). The main aim is to streamline procedures and better address the specific requirements of ATMP developers. The Agency's Committee for Advanced Therapies plays a central role in the scientific assessment of ATMPs, as it provides the expertise needed to evaluate these medicines. Other initiatives include European Commission research programmes, the innovation offices in the national competent authorities and EMA’s PRIME scheme.
Unparalleled access to clinical data - one year on
One year ago today, the European Medicines Agency (EMA) became the first regulatory authority to give open access to clinical data submitted by companies in support of their marketing authorisation applications. EMA’s flagship policy on the publication of clinical data enables citizens, including researchers and academics, to directly access the clinical reports underpinning the regulatory evaluation of a medicine’s clinical efficacy and safety via its clinical data publication website.
Directorate-General Research & Innovation at ECTMIH 2017
DG Research & Innovation participated at the 10th European Congress of Tropical Medicine and International Health with two interactive sessions:
- Preparing for the Next Epidemic: The Need for Global Collaboration
- EU Research Strategy on Neglected Infectious Diseases
Results of the Public Consultation on Transformation of Health and Care in the Digital Single Market
The public consultation drew nearly 1.500 replies and showed a broad support for health related actions in the Digital Single Market. More than 90% of respondents agree that citizens should be able to manage their own data. More than 80% agree that sharing health data can be beneficial. Nearly 55% report not having access to digital health services. More than 80% agree that citizen feedback to healthcare providers and professionals is essential to improve services.
IMI – new brochure on results and projects
The projects supported by the Innovative Medicines Initiative (IMI) are laying the foundations that are helping researchers across Europe, including many in SMEs, to advance their drug development programmes. As of the end of 2016, the IMI community brought together 11. 500 scientists and experts from across Europe and beyond working in 84 projects. Find out more about IMI's commitment towards helping to fast-track medical breakthroughs in their new brochure on results and projects.
Evaluation of the Innovative Medicines Initiative now published
The reports on the evaluation of the seven public-private partnerships, the so-called Joint Undertakings (JUs) under Horizon 2020, and their six predecessors under the previous seventh framework programme, have been published. This includes a Staff Working Document presenting the Commission services' view on the performance of the seven JUs under Horizon 2020. The experts concluded that the Innovative Medicines Initiative “remains both relevant and justified” under Horizon 2020 and that “positive contributions on the drug development process are expected, but results are yet to be realised as the first projects under IMI2 JU only started in 2014”.
- Staff Working Document
- Report on IMI JU Final Evaluation
- Report on IMI2 JU Interim Evaluation
- News Alert
EU–funded project aims at developing an effective Tuberculosis vaccine
Supported by Horizon 2020 with EUR 18.2m, TBVAC2020 research project aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. Over 50% of the global pipeline in TB vaccine candidates currently evaluated in clinical trials originate from EU–funded projects. The European Commission has played a key leadership role in accelerating TB vaccine research and development and ensured a well-coordinated and efficient TB vaccine research consortium.
Registration open! Health, demographic change and wellbeing Info Day
8 December 2017, Brussels
With the principle of better health for all at its core, Horizon 2020's Societal Challenge 1 (Health, demographic change and wellbeing) will be presented during the Health Information Day on 8 December 2017 in Brussels. Societal Challenge 1 (expected budget approx.. EUR 2 billion) focuses on personalised health and care, infectious diseases and improving global health, innovative and sustainable health systems, decoding the role of the environment (including climate change) for health and wellbeing, digital transformation and cybersecurity in health and care.
Related to the Health Open Info Day, the Directorate-General for Research & Innovation supports two events organised on 7 December 2017 (Brussels): Innovation Procurement in health care and the Partnering Event coordinated by the EU–funded project Health-NCP-Net 2.0.
Directorate-General Research & Innovation at the European Health Forum Gastein
DG Research & Innovation invites you to take part in the two interactive sessions organised at the European Health Forum Gastein:
- 4 October, 9:00-11:00, Personalising healthcare: How rare diseases pave the way
- 5 October, 16:00-18:30, Environment & health: Building the evidence base for policy
EU-funded project ALIVER produces new dialysis technology
EU-funded project ALIVER has developed and optimised a novel liver dialysis device called DIALIVE. By 2020 a new dialysis technology could be available and extend the lives of people with cirrhosis long enough for their liver to start recovering or to find a donor for a liver transplant.
EC and EIB grant EUR 20m loan to speed up solutions for the prevention and treatment of antibiotic–resistant infections
This key loan is designed to finance Da Volterra, a French biopharmaceutical company, toward the development in the area of prevention and treatment of antibiotic-resistant serious infectious and hospital-acquired diseases. This financial support is being provided under Horizon 2020, the current EU framework programme for research and innovation., and more particularly the InnovFin Infectious Diseases Finance Facility, which offers bespoke products for financing high-risk projects in the field of infectious diseases.
Personalised medicine days in Toulouse and LondonEU–funded project U-PGx aims to address major challenges and obstacles for the implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. As part of the dissemination and outreaching activities the project will organise the personalised medicine days:
- U-PGx Personalised Medicine Public Day, 17 November 2017, Toulouse, France, under the theme "Pharmacogenomics in Oncology: Deciphering the Ethical, Legal and Societal Issues"
- U-PGx Personalised Medicine Public Day, 6 December 2017, London, UK, under the theme "Is personalised medicine available for all citizens?"
- U-PGx project
New rare disease research goals for the next decade
The International Rare Diseases Research Consortium is proud to announce the new vision and goals for 2017-2027. The new vision will enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention. The European Commission is committed to support IRDiRC's new targets through Horizon 2020, the current EU framework programme for research and innovation.
Commission launches public consultation on Health and Care in the Digital Single Market
The European Commission launches a public consultation today on how Europe should promote digital innovation in health and care, for the benefits of citizens and of health systems in Europe. This consultation will help us to identify how to empower citizens, medical professionals and researchers; to ensure a right for citizens to have an electronic health record that they can access from everywhere in the EU, to improve prevention, rapid response to pandemic threats, personalised treatments and care.
- Press release
- Public Consultation: Transformation Health and Care in the Digital Single Market
- Digital Single Market - consultations
Innovative Medicines Initiative – new calls out
The Innovative Medicines Initiative has launched two Calls for proposals open, giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. The deadline for both calls is 24 October 2017, 17:00, Brussels time.
Antimicrobial Resistance: Commission steps us the fight with new Action Plan
The Commission continues to scale up its fight against antimicrobial resistance (AMR), with the launch of a second European Action Plan.
The new Action Plan is based on a One Health approach and focusses on supporting Member States, particularly in establishing, implementing and monitoring their National Action Plans. It also brings together EU funds and instruments to promote innovation and research against AMR and strengthen the EU's leading role in global fora, notably within the international organisations and with major trade partners.
The EU delegation met the Lithuanian delegation at BIO International Convention
The Lithuanian Minister of Economy, H.E. Mindaugas Sinkevičius, visits the EU pavilion at BIO International Convention. Talks around smart specialization, research infrastructures and the Lithuania’s dramatic rise in the European Innovation Scoreboard were on the agenda.
Fast track to orphan drugs enjoys a full house at BIO 2017
With over 110 participants, the session organised by DG Research and Innovation presented opportunities for public funding and regulatory support for orphan drug development available in Europe and the US with testimonies from companies benefiting from such support and stakeholder collaboration. Representatives of the European Commission, the International Rare Diseases Research Consortium, the US Food and Drug Administration and the European Medicines Agency engaged in a very constructive debate and took questions from the audience.
- European Medicines Agency
- International Rare Diseases Research Consortium
- US Food and Drug Administration
Launch of the African Access Initiative
The Initiative along with a white paper on cancer burden and emerging crisis in Africa, was launched at BIO 2017 in San Diego. Through the European and Developing Countries Clinical Trials Partnership (EDCTP), the European Commission has been actively involved in sub-Saharan Africa. EDCTP's objective in that area is to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases.
- New African Access Initiative
- European and Developing Countries Clinical Trials Partnership
- BIO International Convention
The European Commission opens to the public the EU pavilion at BIO 2017
Directorate General Research and Innovation, European Commission, attends for the 14th consecutive year BIO International Convention, the biggest biotechnology event in the world. The Innovative Medicines Initiative and the European Medicines Agency were our two main partners. The booth notably offers the opportunity to meet with EU-funded and non-funded organisations, as well as US organisations and from other regions of the world which are looking for information about EU R&D programmes as well as EU policies and activities with Member States.
€20 million EU loan to develop new device to quickly identify pathogens causing meningitis and other infectious diseases
An EU loan of €20 million will support a Barcelona-based start-up to develop and commercialise a device capable of identifying within an hour a range of infectious pathogens, such as those contained in meningitis, respiratory or gastro-intestinal infections. This loan is signed under the InnovFin Infectious Diseases Finance Facility.
Katholieke Universiteit Leuven (KU Leuven) and partners developing dual vaccine against yellow fever and rabies, supported by Horizon 2020
The RABYD-VAX consortium, led by KU Leuven, is developing a cheap and easy-to-produce vaccine against rabies AND yellow fever which allows a stable temperature during transport and storage and thus guarantees a better efficiency compared to the existing vaccines.
EMA publishes framework and action plan for closer interaction with academia
In the context of the European medicines regulatory network, the European Medicines Agency (EMA) has developed a framework and an action plan to reinforce collaboration with the academic community.
ICPerMed Action Plan for Personalised Medicine published
The International Consortium for Personalised Medicine (ICPerMed), comprising over 30 European and international members, have published a consensus Action Plan on the research and development actions needed to further advance personalised medicine.
Ebola vaccine immune responses of results obtained in EBOVAC1
EU-funded H2020 IMI research project on Ebola vaccine, EBOVAC1, induced durable immune response 1-year after vaccination.
EU support the fight against tuberculosis: Reversion of antibiotic resistance in Mycobacterium tuberculosis
The newly identified molecule SMARt-420 has shown effective results in clearance promotion of multidrug-resistance strains of Mycobacterium tuberculosis from the lungs of mice.
The work received support from the European Research Council, Marie Skłodowska-Curie actions research fellowship and the EU collaborative research grant MM4TB.
Health National Contact Points Network (Health NCP Net Project)
Estimating the risk of microcephaly following Zika virus infection
The Horizon 2020 project ZIKAlliance published a study in the Bulletin of the World Health Organization, estimating the risk of microcephaly in women infected with Zika virus during pregnancy.
The study found that the risk varies substantially across Brazil, and was affected by different factors, such as the geographical area.
European Medicines Agency (EMA) workshop on Seventh Framework Programme (FP7) small-population research methods projects and regulatory application
Three FP7 projects, Asterix, IDeAl and InSPiRe, are funded by the EU to develop new methodology on design and analysis of small population clinical trials since 2013.
Third conference of the International Rare Diseases Research Consortium (IRDiRC)
The 3rd IRDiRC Conference took place in Paris on 8-9 February 2017, welcoming around 300 participants from around the globe, including rare disease researchers, clinicians, funders, political decision makers, patient organisation representatives and pharmaceutical industry members. Five years have passed since the official launch of IRDiRC and considerable advances have been made in rare diseases research. Indeed, the goal set by IRDiRC of delivering 200 new therapies for rare diseases and means to diagnose most rare diseases by 2020 has been passed.
Advanced therapy medicines: towards increased development and patient access
The European Medicines Agency (EMA) has published today a set of ideas to better support development and expand patients’ access to high quality, safe and effective advanced therapy medicinal products (ATMPs).
€1 Million was awarded to Minicare HNL, the winner of the Horizon Prize 'Better use of antibiotics'
On 6 February 2017, Carlos Moedas, EU Commissioner for Research, Science and Innovation, awarded a €1 million Prize to Minicare HNL , for a finger prick test that can diagnose in less than ten minutes a bacterial infection and identify if a patient can be treated safely without antibiotics.
International Conference on Poverty-related and Neglected Diseases
Directorate General Research and Innovation, research funders, academia and policy makers gather tomorrow to discuss the conclusions and recommendations of the study on Poverty-related and Neglected Diseases (PRND). The study aimed to evaluate the role of EU research on PRND in contributing to achieving universal health coverage and improving population health in low and middle–income countries.
Study of volunteer blood donors in Martinique provides new information about Zika virus infection
A large study of volunteer blood donors has been performed in Martinique Island during the local Zika outbreak in 2016 by Pierre Gallian and collaborators. The research team is part of ZIKAlliance, a project funded by the European Union Horizon 2020 Research and Innovation Programme to better understand the clinical and fundamental aspects of infections by Zika virus.
Coalition for Epidemic Preparedness Innovation launched at the WEF Annual Meeting 2017
Launched today at the World Economic Forum (WEF) Annual Meeting in Davos was of the Coalition of Epidemic Preparedness Innovation (CEPI) – a global non-profit public-private partnership founded by the Government of Norway, the Government of India, the Bill & Melinda Gates Foundation, the Wellcome Trust and the WEF. The European Commission will contribute to CEPI's overall objectives in the area of epidemic preparedness, which are in line with that of the European Commission, and plans to co-fund actions with CEPI, such as through the Innovative Medicines Initiative.
- The Lancet
- The New England Journal of Medicine
- Wellcome Trust Press Release
- Watch: Let's #OutsmartEpidemics
European Medicines Agency – 2016 highlights for human medicines
EMA has published an overview of its key recommendations of 2016 in relation to the marketing authorisations of new medicines and the safety monitoring of authorised medicines.
EU launches personalised medicine projects to foster treatment of inflammatory disorders
EU-funded flagship projects, MultipleMS and SYSCID, receive EUR 15m each. These two projects focus on precision diagnostics and therapeutic targets in chronic inflammatory and autoimmune disorders as a major health care burden of industrialised societies. Chronic inflammatory diseases and autoimmunity constitute a group of incurable disorders of the immune system with a lifetime prevalence of over 10% in Europe.
Launch of a joint trans-national call for pathway analysis across neurodegenerative diseases
On 9 January 2017, the EU Joint Programme – Neurodegenerative Disease Research (JPND) has launched a joint trans-national call for pathway analysis across neurodegenerative diseases.
The €23 million call responds to a need of targeted investment to better understand the fundamental links between different diseases. It is made available to applicants from 20 countries.
Malaria, HIV vaccine achievable ‘in one or two decades’ – Dr Leonardo Santos Simão
We will see vaccines for malaria and HIV within the next one or two decades, predicts Dr Leonardo Santos Simão, the former health minister of Mozambique, who has been appointed High Representative South of the European & Developing Countries Clinical Trials Partnership (EDCTP), which aims to accelerate the development of new treatments, vaccines and diagnostic tools for diseases in sub-Saharan Africa.
Public stakeholder consultation
Interim evaluation of Joint Undertakings operating under Horizon 2020. All citizens and organisations are welcome to contribute to this consultation. Contributions are particularly sought from researchers, industry, entrepreneurs, innovators and all types of organisations that have participated in Horizon 2020 and in calls for proposals published by the Joint Undertakings in particular.
Workshop on adaptive pathways – discussion on development approach for medicines addressing unmet medical needs
The European Medicines Agency in collaboration with the European Commission is organising a workshop on 8 December 2016 to gather the views of stakeholders on the adaptive pathways approach for medicine development. The registration is now closed but you can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
RTD co-organises GloPID-R Zika Virus Research Workshop
Diseases like Zika virus infection do not respect borders, so scientists across the globe must work together to fight them. To reinforce such collaboration, a group of international scientists and research funders held a workshop in São Paulo on 30 November – 2 December 2016.
The workshop allowed for active exchanges on how to better collaborate together to ensure high quality, harmonised research addressing many of the remaining research questions on Zika virus infection and its complications. Opportunities identified for further collaboration include the integration of different cohort studies for a better understanding of the clinical spectrum of Zika virus infection, the need for consensus on experimental protocols for studies on pathogenesis, or on extending external quality assurance for diagnostic tools. Concrete initiatives for collaboration were launched, such as on vector studies or between the clinical trial and preparedness networks. The importance of timely data sharing in the context of public health emergencies was emphasised throughout the workshop.
The workshop was organised in the context of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), and was hosted by the University of São Paulo.
EU-funded project coordinator, Jennifer Zeitlin, receives the "Stars of Europe" Award
Jennifer Zeitlin, coordinator of EU-funded project EPICE, received yesterday the "Stars of Europe" Award. The EUR 4 mil project explored the use of evidence based practices for the care of very preterm infants in 19 regions from 11 EU Member States. Under the auspices of the French Ministry of National Education and Research, this award is given to coordinators of European research and innovation projects supported by a French structure. The distinctions are selected by a high-level jury closely looking at the quality of scientific production, the creation of value and jobs, the societal dimension, the 'open to the world' aspect and gender balance. The Stars are an encouragement addressed to all actors, academic or private, to participate to what is now Horizon 2020, the EU framework programme for research and innovation.
TRANSCAN-2: Third Joint Transnational Call for Proposals (JTC 2016)
Launch of the Third Joint Transnational Call for Proposals (JTC 2016) on “Minimally and non-invasive methods for early detection and/or progression of cancer ”
European Medicines Agency Workshop: "Measuring the impact of pharmacovigilance activities"
The European Medicines Agency (EMA) is organising a workshop to discuss methods to measure the impact of pharmacovigilance activities on patient safety. The event will be web-streamed from the EMA premises in London, from 13:00 UK time on 5 December to 17:00 UK time on 6 December 2016.
Registrations are now open for the 3rd IRDiRC Conference
The 3rd International Rare Diseases Research Consortium (IRDiRC) Conference gathers stakeholders from around the world to share their experience, knowledge and points of view to shape and advance rare diseases research through foundational, diagnostics, therapeutics and policy development. The event will be held on 8-9 February 2017 in Paris, France.
Launch of the ICPerMed: Accelerating a personalised medicine approach for citizens
International Consortium for Personalised Medicine (ICPerMed) will support the implementation of personalised medicine and set out a policy framework covering all steps of the innovation cycle from research and innovation through to the uptake of personalised medicine in healthcare. It will address the following Commission priorities: boosting jobs, growth and investment, a connected digital market, and a stronger global actor.
Get involved in the next H2020 Health proposals!
Health NCP Net (HNN2.0) and Enterprise Europe Network (EEN) are organizing the next Decentralized Health Brokerage event in Zagreb (Croatia), on 19 January 2017. Registrations are open until 16 December 2016.
European Parliament Workshop: "Understanding the Human Brain - A new era of big neuroscience"
The Science and Technology Options Assessment is organising a workshop in Brussels where key leading representatives of three large-scale brain research initiatives from Europe, the United States and Japan will present an overview of their status, achievements, opportunities for cooperation, and future plans. The workshop will be webstreamed on 29 November 2016 from 14h30 to 17h00.
The European Commission announces shortlist for the €1m Better Use of Antibiotics Horizon Prize
Today, on European Antibiotic Awareness Day, the European Commission announced the shortlisted candidates for the €1m Better Use of Antibiotics Horizon Prize – ImmunoPoC, Minicare HNL and PulmoCheck – for their ideas on developing and/or bringing-to-market a test to quickly identify whether a patient can be treated safely without antibiotics.
International Human Epigenome Consortium celebrates major coordinated paper release
One of the great mysteries in biology is how the many different cell types that make up our bodies are derived from a single cell and from one DNA sequence, or genome. A collection of 41 coordinated papers now published by scientists from across the International Human Epigenome Consortium sheds light on these processes, taking global research in the field of epigenomics a major step forward. EU–funded project BLUEPRINT is a part of the Consortium and reunited 42 leading European universities, research institutes and industry entrepreneurs. As many as 26 of these coordinated papers were contributed by the EUR 30 mil project.
The European Commission launches a public consultation on the Paediatric Regulation
The European Commission has launched a public consultation to get views and feedback from stakeholders, to support the Commission in drafting its second report on the Paediatric Regulation after nearly ten years of implementation. The consultation is open until 20 February 2017.
Innovative funding for SMEs in Europe – BIO-Europe 2016
From left to right: Pierre Meulien, Shiva Dustdar, Cornelius Schmaltz, Ralf Schmidt
The Directorate General for Research and Innovation, European Commission, welcomed the Innovative Medicines Initiative (IMI), the European Investment Bank and, Biovotec, a successful project under the SME Instrument, at a session on SME funding in BIO-Europe 2016. The event is Europe's largest partnering conference serving the global biotechnology industry. Being present, we are able to give an overview of the SME Instrument and introduced other Horizon 2020 SME–oriented facilities, such as InnovFin, the EU Finance for Innovators as well as IMI future opportunities.
- EU funding for Health Research SMEs
- The Innovative Medicines Initiatives – Innovative funding for SMEs in Europe
- EIB support in life sciences
- Biovotec – SME Instrument success story
The European Commission has published the review of its Action Plan against the rising threats from antimicrobial resistance
This evaluation assesses the impact of the AMR Action Plan which covers the period 2011-2016. Specifically, the evaluation assesses whether the 12 actions contained in the Action Plan were relevant to address the problems identified, and if these actions were effective, efficient, coherent with other EU policies in combatting AMR and whether added value was provided by EU action.
Registrations are open for the launch event of the European Human Biomonitoring Initiative
The European Human Biomonitoring Initiative (HBM4EU) is a joint effort of 26 countries and the European Commission, co-funded by Horizon 2020. HBM4EU will thereby provide better evidence of the actual exposure of citizens to chemicals and the possible health effects to support policy making.
The Directorate-General for Research and Innovation releases the Personalised Medicine Conference Report
The report addresses the broader policy perspective and challenges by showcasing both integrated healthcare models in Member States and business approaches which involve patients more directly in their healthcare. The Personalised Medicine Conference 2016 took place in Brussels (1-2 June 2016) and attracted 600 participants on site and over 2.000 online.
European Union invests €45 million into research to combat the Zika disease
The EU is investing €45 million in research to combat the outbreak of the Zika virus disease and other emerging infections transmitted by mosquitoes. The significant funding from Horizon 2020, the EU's research and innovation programme, will support research on treatments, diagnostics and vaccines, as well as better risk assessment for Zika.
EU-funded project TRANSCAN-2 will launch the Joint Transnational Call for research proposals in December 2016
Interested researchers and/or research teams are advised to prepare and make the necessary contacts and arrangements towards preparing applications. The topic of the call will be: “Minimally and non-invasive methods for early detection and/or progression of cancer”.
EU-funded projects met to share latest results on cardiovascular research
With a total EU contribution of approximatively EUR 18 m throughout their lifetime, ongoing projects CarTarDis, CVgenes@target and TransCard gathered to share their latest results on cardiovascular research. This open sharing of technologies and most recent breakthroughs leads to optimal dissemination of latest developments supported by the EU and thus aids the increase of output from these research projects in a very relevant disease area.
EDCTP appoints High Representatives for Europe and Africa
The High Representatives will act as goodwill ambassadors for EDCTP in order to increase the visibility of the programme and promote partnerships with other EDCTP stakeholders in the fight against poverty-related and neglected diseases in Africa, Europe and globally.
PRIME – Paving the way for promising medicines for patients
PRIME is a scheme launched by the European Medicines Agency to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.
EU SME Cellectis wins 2016 Most Innovative European Biotech SME Award for Healthcare
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells won EuropaBio’s 2016 Most Innovative European Biotech SME Award for the healthcare category. The Awards program represents a unique annual initiative that recognizes innovative biotech small-and medium-sized enterprises (SMEs) in Europe and the crucial role that they play in answering some of society’s greatest challenges through biotechnology. Cellectis was involved as a participant in 2 EU-funded health projects under the Seventh Framework Programme for Researchers, namely ATECT (Advanced T-cell Engineered for Cancer Therapy) and SCR&TOX (Stem Cells for Relevant Efficient Extended and Normalized Toxicology).
GACD funds innovative research into prevention and management of lung diseases
Members of the Global Alliance for Chronic Diseases are funding more than thirteen international research projects into the prevention and management of chronic lung diseases. The research is to take place in more than 30 countries across the globe and represent over USD 55 million of research funding over 3-5 years with a focus on implementation and intervention research in low-and middle-income countries, vulnerable populations in high‐income countries and aboriginal communities.
EU-US collaboration to boost medicine development for rare diseases
The European Medicines Agency and the United States Food and Drug Administration have set up a new ‘cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases. The cluster will provide a forum for confidential exchange of draft documents, policies under development, and more detailed information supporting the scientific basis for decision making on medicine development.
The Eighth EDCTP Forum, 6-9 November 2016, Zambia
The biennial EDCTP Forum is one of the most prominent conferences on HIV/AIDS, tuberculosis, malaria and other neglected infectious diseases prevalent in Africa and is expected to gather some 600 delegates. The Eighth Forum is organised by EDCTP in partnership with the Ministry of Health of the Republic of Zambia. EDCTP will award four international prizes dedicated to the promotion of scientific research, improved health and Africa-European collaboration.
Independent Advisory Panel on characterising flavours in tobacco products - Call for expression of interest
The European Commission is looking for experts in sensory analysis, chemical analysis and statistics to join a newly established independent advisory panel assisting Member States and the Commission in determining whether tobacco products have a characterising flavour.
Innovative Medicines Initiative publishes Call 10 topics
The world's biggest public-private partnership in the life sciences publishes topics for Call 10, which is scheduled for launch in autumn 2016. All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.
International epigenetics EU–funded project delivers beyond expectation
Researchers from the BLUEPRINT project join their international colleagues this week at the 2016 International Human Epigenome Consortium (IHEC) conference in Brussels to report the latest results in understanding blood cell development and blood disease. BLUEPRINT received €30 million from the European Union to decipher the role of epigenetics in normal and diseased blood cells. Epigenetic effects alter the activity of genes without altering the DNA code, and play an important role in development and disease.
Save the date: Third conference of the International Rare Diseases Research Consortium (IRDiRC)
8-9 February, 2017 at the conference center of Université Pierre et Marie Curie in Jussieu, Paris, France.
EU invests over €1bn to fight antimicrobial resistance
Deaths from drug-resistant microbes could be 10m a year by 2050. The European Union (EU) has been committed to combating AMR since 1999, and has continued to prioritise research on AMR in its Horizon 2020 research programme. As part of this commitment, the EU has spent more than €1 billion on AMR research.
EDCTP publishes the list of calls
Having its main focus on Sub-Saharan Africa, the European & Developing Countries Clinical Trials Partnership puts together a list of calls for proposals which vary from vaccines for poverty-related diseases and strategic actions supporting large-scale clinical trials to a wide range of fellowships meant to support the researchers of tomorrow.
Health National Contact Points Meeting – Conclusions and testimonials
Directorate Health, DG Research and Innovation, European Commission, organised together with the EU-funded projects HNN 2.0 and Fit for Health the Health NCP Meeting. The purpose of the event was to better advise the representatives of the Member States (NCPs) on how to respond to the Horizon 2020 applicants as regards to finding the right project partners for the upcoming 2017 Health calls, submitting proposals and also budget wise.
The European Commission publishes the Work Programme 2016–2017 in the area of Health, demographic change and well-being
TheThe EC confirmed the calls and other actions of the second year of the two-year work programmes setting out funding opportunities for 2017. Horizon 2020 Work Programme will contribute to the Jobs, Growth and Investment Package helping to strengthen Europe’s global competitiveness through innovation to create new and sustainable jobs and promote growth. Horizon 2020 Societal Challenge 1 focuses on personalised health and care and benefits from a budget of EUR 331.76 million.
The European Commission participates at the 21st International AIDS Conference, Durban, South Africa
The European Commission together with the European and Developing Countries Clinical Trial partnership is hosting the satellite symposium " Every Mother, Every Child: Closing the Gaps in HIV management" within the AIDS2016 in Durban. During the symposium main experts on maternal, child and adolescent health will highlight prominent advances in the field while also presenting and discussing the major research bottlenecks. Accomplishments of recent EU and EDCTP-funded projects and the future plans in this area will also be presented.
EU-funded initiative COMET organises meeting on preparation of health research outcomes
The COMET Initiative is working to improve the quality of health care by facilitating the preparation of core outcome sets which could be used in research, including randomised trials and systematic reviews, in a specific topic area. The sixth COMET meeting will be held in Amsterdam on 10-11 November 2016. The programme will provide opportunities for individuals interested in the development and application of core outcome sets across different areas of health and social care to share ideas and learn more.
Health Information Day – Registration closed
The Health Information Day on Horizon 2020 Societal challenge 1 (SC1) calls for 2017 will take place on 8 July in Brussels. SC1 updated Work Programme 2017 offers calls for proposals with an overall budget of about € 400 million.
Advisory Group publishes report
The Advisory Group report on the Horizon 2020 Societal Challenge 1 "Health, Demographic Change and Well-being" for period 2018-2020 is now available.
Personalised Medicine Conference 2016 – last chance to register
Europe is a leader in personalised medicine, an interdisciplinary field which will drive the health research and innovation agenda for years to come in view to improve healthcare. The conference will introduce a new collaboration among health research funding and policy making organisations called the International Consortium for Personalised Medicine (IC PerMed). Please register by 26 May, midnight.
Launch of the Horizon Birth Day Prize
The Birth Day prize will be awarded for a solution that improves care and reduces death and illness of mothers and babies during delivery in a health facility around the world.
Zika International Meeting Paris
The speed and extent of this outbreak, which the WHO declared a Public Health Emergency of International Concern, requires open collaborations between researchers, the public health community and the public. Direction General Research, European Commission, attends this 2-day meeting on 25-26 April 2016. The purpose of the meeting is to bring together scientists and public health professionals around the world working on Zika
The European Commission hosts the Global Health Policy Forum on Access to Medicines
On 26 April 2016, the European Commission will organise the second Global Health Policy Forum in 2016. The main target includes access to medicines with a particular focus on WHO essential medicines and the impact of voluntary licensing on access to medicines. The European Commission organises the Global Health Policy Forum four times a year to meet and exchange information with representatives from a variety of different institutions, including international bodies such as the WHO and UN, civil society organisations like Médecins Sans Frontières, private sector companies and academic institutions. The first Global Health Policy Forum in 2016 focused on health and migration.
Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA
We are delighted to see such positive results produced by a consortium supported with grants from the Ebola+ programme. These and the many other Ebola studies underway with the European Commission and IMI support show that cooperation research and public-private partnerships can be formed with great speed to develop innovative solutions for today’s most pressing global health threats. Only by joining forces as an international community can we prevent, control, and end pandemics.” said Ruxandra Draghia-Akli, Director, Health Directorate, European Commission.
Health Information Day
SAVE THE DATE! The Health Information Day on Horizon 2020 Societal challenge 1 calls for 2017 will take place on 8 July in Brussels. The event targets a wide range of participants, mostly applicants for the H2020 research programme
EU supports Zika research with €10 million
The European Commission is today releasing €10 million for research on the Zika virus, currently affecting large parts of Latin America.
EU needs to step up its research and innovation performance, report finds
Publication of the RTD Report: 'Science, Research and Innovation performance of the EU 2016: a contribution to the open innovation, open science, open to the world agenda'. The report makes the connection between investing in Research & Innovation and economic growth.
23-25 November 2017, Antwerp, Belgium - 6th International Fluid Academy Days (IFAD)
25-28 November 2017, Copenhagen, Denmark - 42nd World Small Animal Veterinary Congress and FECAVA 23rd Eurocongress
8 December 2017, Brussels (Charlemagne building), Belgium - Info Day, Horizon 2020 – 'Health, demographic change and wellbeing'
Read about our Success Stories